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NW457 was assessed by Western blot, flow cytometry, 
caspase activity, colony formation, wound healing, viability, 
and transmigration assays. 
Results: The novel small-molecule HSP90 inhibitor NW457 
interferes with the radioresistant phenotype of human 
glioblastoma cells as it sensitized LN229 and T98G cells 
towards irradiation-induced clonogenic cell death and 
potently induced apoptosis. NW457 provoked destabilization 
of critical regulators of the DNA damage response (ATM, ATR, 
CHK1 and CHK2) and induced activation of caspase-3 with 
subsequent PARP cleavage. Additionally, NW457 
demonstrated potent anti-invasive activities by decreasing 
the inherent migration of LN229 cells as well as inhibiting 
irradiation-induced hypermigration. 
Conclusions: Taken together, our data on HSP90 inhibition as 
a clinically relevant, novel glioblastoma treatment concept 
suggests that the novel small-molecule inhibitor NW457 might 
improve the efficacy of radiotherapy via a dual mechanism 
involving (i) attenuation of radioresistance through induction 
of apoptosis and impairment of the DNA damage response 
and (ii) inhibition of both inherent and radiation-induced 
migration. 
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Purpose/Objective: Tumor hypoxia is prognostic for poor 
outcome after radiotherapy (RT). A method for non-invasive 
assessment of hypoxia is positron emission tomography (PET) 
using radiotracers that accumulate in hypoxic tissue volumes. 
However, many factors that impact tracer accumulation are 
not yet fully understood. Here, mathematical simulations 
may help to further investigate hypoxia PET image formation. 
The purpose of this study is to validate a dedicated 
simulation model against experimental data. The model can 
readily be adapted to a variety of conditions, such as 
different human head and neck cancer (HNC) cell lines (CLs). 
Materials and Methods: Immunohistochemically stained 
sections of tumor xenografts were available for nine HNC cell 
lines, providing information on hypoxia (pimonidazole), 
perfusion (Hoechst 33342), and vessel distribution (CD31). 
They were used to generate 2D maps of perfused blood 
vessels, based on which tissue oxygenation and the 
distribution-retention dynamics for the hypoxia PET tracer 
FMISO were mathematically simulated in order to generate 
FMISO distribution patterns four hours post injection. 
The model includes a Michaelis-Menten relation to describe 
the oxygen consumption inside the tissue. M0, representing 
the maximum oxygen consumption, was chosen as parameter 
for CL-specific optimization as this parameter strongly 
influences tracer distribution. Simulations were optimized for 
M0 on each tumor slice to reach optimum correlations 
between FMISO concentration and pimonidazole staining 
intensity. 
Results: After optimization, very high point-to-point 
correlations up to R2 = 0.85 were found for individual tissue 
sections. Experimental pimondazole staining and simulations 
showed good visual agreement, confirming the validity of the 
approach. Mean correlations per CL varied significantly (p2 
ranging from 0.24 to 0.53.  
The derived maximum oxygen consumption rate M0 differed 
significantly (p0 was found to correlate significantly with the 
previously published BrdU labeling index for these CL (p2 
consumption. No correlation was found with TCD50. 
 
 
 
Conclusions: It is technically feasible to simulate FMISO 
distributions that match the pimonidazole retention patterns 
observed in vivo. Good agreement can be obtained for 
multiple CLs by optimizing the individual oxygen consumption 
rate, M0, whose optimum value differed significantly between 
CLs. Optimized M0 correlated with the proliferation marker 
BrdU, but not with TCD50. 
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Purpose/Objective: Tumor physiology predicts response to 
radiotherapy. The aim of this study was to examine and 
correlate tumor vascularity and glucose metabolism based on 
[18F]-FDG uptake and perfusion maps. 
Materials and Methods: 42 patients with head and neck 
cancer (15 patients T1/T2 and 27 T3/T4), who underwent 
[18F]-FDG PET/CT (270 - 410 MBq FDG) examination together 
with simultaneous perfusion CT (CTP) (40 mL of contrast, 1 s 
rotations time with 1 image/s, cine duration 50 s, 80 mA, 100 
kV), were included in the study. A radiation oncologist 
contoured primary tumor (GTVPT) and lymph node metastases 
(GTVLN) in CTP. Using the gradient-based method GTVPET was 
auto-segmented. Perfusion maps were calculated using 
singular value decomposition method with in-house 
developed software. Blood volume (BV), blood flow (BF), 
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mean transit time (MTT) and standardized uptake value (SUV) 
were determined for the following structures: GTVPET, GTVPT, 
GTVLN, as well as 5 mm and 10 mm margins from GTVPT and 
GTVLN. The 10 mm margin corresponds to the PTV and 5 mm 
margin was added to the analysis to study the signal changes 
in the PTV periphery. Voxel-wise Spearman correlations of 
perfusion parameters (BV, BF, MTT) and SUV were studied for 
each patient and each volume. Mean correlation coefficients 
corresponding to each structure were calculated to examine 
the population correlation. Moreover, correlations of mean 
BV, BF and MTT with SUVmean and SUVmax were tested. 
Differences of median values of mean BV, BF and MTT for 
various volumes among the patients population were 
investigated using paired Wilcoxon test. The significance 
level chosen for correlation study was 0.05 and for Wilcoxon 
test 0.01. 
Results: Based on the voxel-wise study no population-based 
correlation between perfusion parameters and SUV was 
found. A significant correlation was observed between mean 
MTT and SUVmean in the GTVPET of the PT (p=0.05) with a 
correlation coefficient of r = 0.73 for T1/T2 tumors and of r = 
0.55 for T3/T4. For both PTVPT and PTVLN, significant 
correlations between mean BF and SUVmean were found with 
the same correlation coefficient r = 0.44. Such dependencies 
were not observed for GTVPT and GTVLN, but the similar 
correlation was found for alone 5 mm (r = 0.50) and 10 mm (r 
= 0.44) margins from GTVLN. A difference was found for 
median value of BV between GTV and its 5 mm margin for PT 
and LN for all patients. This difference was observed for 
GTVPT corresponding to stage T3/T4, but was not significant 
for stage T1/T2. The median MTT was found to be 
significantly higher in GTVPT in comparison to its 5 mm 
margin. 
Conclusions: Tumor and surrounding normal tissue exhibit 
differential CT perfusion parameters. Analysis of PET and CT 
perfusion showed a positive correlation for SUVmean and MTT 
for the GTVPET. Therefore increased tumor perfusion and 
glucose metabolism seem to be part of a specific tumor 
physiology. Further studies are needed to investigate if 
specific tumor physiology predicts for response or resistance 
to radiotherapy.  
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Purpose/Objective: Neo-adjuvant chemoradiotherapy (nCRT) 
followed by surgery has become the standard treatment with 
curative intent for esophageal cancer patients. Despite the 
improved overall survival compared to surgery alone, the 
patients' quality of life (QoL) remains low due to the high 
burden of esophagectomy and high incidence of post-
operative complications. QoL would be improved by 
postponing surgery and a wait-and-see policy for patients 
with a complete pathological response to nCRT. Therefore, 
we investigated the feasibility of FDG-PET/CT derived 
variables to predict this pathological response. 
Materials and Methods: Patients with histologically proven 
esophageal cancer (stage IIA – IIIC) that received a baseline 
PET/CT scan 1-4 weeks prior to the start of the nCRT were 
included. A pre-surgery PET/CT scan was made 5-7 weeks 
after the last radiation dose. Gross tumor volumes (GTVs) 
were delineated on the baseline diagnostic PET/CT scan or 
were copied from the radiotherapy planning CT scan. The 
volume of the GTV and the mean, maximum and peak 
standard uptake values (SUVmean, SUVmax, and SUVpeak, 
respectively) within the GTV were determined. The 
metabolic tumor volume (MTV) was defined as the region 
with a SUV > 40% of SUVmax, and SUVmeanMTV was the mean SUV 
within this volume. The total lesion glycolysis (TLG) was 
defined as MTV x SUVmeanMTV. Tumor response to nCRT was 
evaluated using the Mandard regression classification (TRG 1-
5) on the pathological specimen after surgery. Patients were 
divided in responders (TRG 1-2) and non-responders (TRG 3-5) 
for statistical analysis. 
Results: Imaging and clinical results of 25 patients treated 
since mid-2012 were available. In total 28% (N=7) patients 
showed a pathological complete response (TRG 1) at the 
primary tumor site, and 32% (N=8) patients had a TRG 2, 
these patients were identified as responders. All other 
patients (40%, N=10) had a higher TRG and were defined as 
non-responders.  
Looking only at the baseline or pre-surgery scan was not able 
to show a significant difference between both groups for any 
of the investigated variables. However, the relative changes 
between the two PET/CT scans were prognostic. Responders 
had a significantly higher reduction in SUVmax (-50±26 vs. -
16±41, P=0.017), SUV-peak (-52±27 vs. -19±40, P=0.021) and 
SUVmeanMTV (-51±30 vs. -18±43, P=0.031), also shown in figure 
1. Multivariate analysis and external validation is ongoing. 
 
Conclusions: The relative change in FDG-uptake at the 
primary tumor site before and after nCRT has a prognostic 
value for response assessment of esophageal cancer patients. 
Responders showed a significantly larger decrease in uptake 
than non-responders. The prediction of pathological response 
using two PET/CT scans could be a useful method for future 
treatment decisions.  
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